SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2002
Interferon Sciences Research Partners, Ltd.
-------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 2-89332 22-2502556
- --------------- -------------- ----------
(State or other (Commission (I.R.S. Employer
jurisdiction of File Number) Identification No.)
incorporation)
783 Jersey Avenue, New Brunswick, New Jersey 08901
- -------------------------------------------- ------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (732) 249-3250
N/A
-----------------------------------------
(Former name or former address, if changed since last report)
Item 4. Changes in Registrant's Certifying Accountant.
- ------ ----------------------------------------------
KPMG LLP was previously the principal accountants for Interferon Sciences
Research Partners, Ltd. On November 6, 2002, that firm resigned.
In connection with the audits of the two fiscal years ended December 31, 2001,
and the subsequent interim period through November 6, 2002, there were no
disagreements with KPMG LLP on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedures, which
disagreements if not resolved to their satisfaction would have caused them to
make reference in connection with their opinion to the subject matter of the
disagreement.
The audit reports of KPMG LLP on the financial statements of Interferon Sciences
Research Partners, Ltd. as of and for the years ended December 31, 2001 and
2000, did not contain any adverse opinion or disclaimer of opinion, nor were
they qualified or modified as to uncertainty, audit scope, or accounting
principles, except as follows:
KPMG LLP's report on the financial statements of Interferon Sciences Research
Partners, Ltd. as of and for the years ended December 31, 2001 and 2000,
contained a separate paragraph stating that "the Partnership has no assets and
is ultimately reliant on Interferon Sciences, Inc. for funding. As indicated in
Note 6 to the financial statements, Interferon Sciences, Inc. has suffered
recurring losses from operations, has an accumulated deficit, a working capital
deficiency, and has limited liquid resources. These factors raise substantial
doubt about the Partnership's ability to continue as a going concern. The
financial statements do not include any adjustments that might result from the
outcome of this uncertainty".
A letter from KPMG LLP is attached as Exhibit 16 to this Form 8-K.
Item 7. Financial Statements and Exhibits.
- ------ ---------------------------------
(c) Exhibits.
16. Letter from KPMG LLP regarding the information contained herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Interferon Sciences, Inc.
Date: November 25, 2002 By: /s/ Lawrence M. Gordon
-------------------------------------
Lawrence M. Gordon
Chief Executive Officer
Exhibit 16
November 25, 2002
Securities and Exchange Commission
Washington, D.C. 20549
Ladies and Gentlemen:
We were previously principal accountants for Interferon Sciences Research
Partners, Ltd. and, under the date of February 20, 2002, we reported on the
consolidated financial statements of Interferon Sciences Research Partners, Ltd.
as of and for the years ended December 31, 2001 and 2000. On November 6, 2002,
we resigned. We have read Interferon Sciences Research Partners, Ltd.'s
statements included under Item 4 of its Form 8-K dated November 25, 2002, and we
agree with such statements.
Very truly yours,
/s/ KPMG LLP